Literature DB >> 15030362

Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial.

M Weiner, A Stein, S Cash, J de Leoz, J-D Fine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15030362     DOI： 10.1046/j.1365-2133.2004.05816.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

Review 1.  Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.

Authors:  Jean Christopher Chamcheu; Gary S Wood; Imtiaz A Siddiqui; Deeba N Syed; Vaqar M Adhami; Joyce M Teng; Hasan Mukhtar
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

2.  Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.

Authors:  Christine Chiaverini; Coralie Roger; Eric Fontas; Emmanuelle Bourrat; Eva Bourdon-Lanoy; Christine Labrèze; Juliette Mazereeuw; Pierre Vabres; Christine Bodemer; Jean-Philippe Lacour
Journal:  Orphanet J Rare Dis       Date:  2016-03-25       Impact factor: 4.123

3.  Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

Authors:  Amy S Paller; John Browning; Milos Nikolic; Christine Bodemer; Dedee F Murrell; Willistine Lenon; Eva Krusinska; Allen Reha; Hjalmar Lagast; Jay A Barth
Journal:  Orphanet J Rare Dis       Date:  2020-06-23       Impact factor: 4.123

Review 4.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

5.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.